(NASDAQ: INSM) Insmed's forecast annual revenue growth rate of 67.06% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Insmed's revenue in 2025 is $447,022,000.On average, 21 Wall Street analysts forecast INSM's revenue for 2025 to be $108,662,832,456, with the lowest INSM revenue forecast at $91,816,361,139, and the highest INSM revenue forecast at $121,032,693,658. On average, 20 Wall Street analysts forecast INSM's revenue for 2026 to be $249,529,958,730, with the lowest INSM revenue forecast at $188,107,199,658, and the highest INSM revenue forecast at $333,559,705,516.
In 2027, INSM is forecast to generate $455,978,676,722 in revenue, with the lowest revenue forecast at $301,142,138,228 and the highest revenue forecast at $669,252,145,722.